OncoMatch/Clinical Trials/NCT06487481
Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma
Is NCT06487481 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies non-drug interventions for adrenocortical carcinoma (acc).
Background: Adrenocortical carcinoma (ACC) is a rare cancer of the adrenal glands. ACC often returns after tumors are removed with surgery. Less than 35% of people with ACC survive 5 years after diagnosis. Objective: To test a new type of external beam RT before surgery in people with ACC. Eligibility: People aged 18 years and older with ACC that came back after treatment but may be safely removed with surgery. Design: Participants will be screened. They will have a physical exam with blood and urine tests. They will have tests of their heart function. They will have imaging scans. A small sample of tumor tissue may be collected if one is not available. They will undergo laparoscopy: Small incisions will be made in the abdomen so that a thin tube with a light and camera can be inserted to view the organs. RT comes from a machine that aims radiation at tumors. Participants will receive preoperative RT in daily fractions over approximately 2-3 weeks, followed by a planned surgical resection about 4 weeks after the completion of RT. Visits will last 30 to 60 minutes. Participants will undergo surgery to remove their tumors about 4 weeks after they finish RT. They will stay in the hospital 1 to 3 weeks after surgery. Participants will have follow-up visits for 10 years after surgery.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: abdominal radiation therapy
Prior abdominal radiation therapy
Cannot have received: chemotherapy
Participants who have received chemotherapy ... within the last 4 weeks prior to starting treatment and/or have not recovered from toxicities to less than grade 2 CTCAE
Cannot have received: immunotherapy
Participants who have received ... immunotherapy ... within the last 4 weeks prior to starting treatment and/or have not recovered from toxicities to less than grade 2 CTCAE
Cannot have received: investigational therapy
Participants who have received ... investigational therapy ... within the last 4 weeks prior to starting treatment and/or have not recovered from toxicities to less than grade 2 CTCAE
Cannot have received: radiotherapy
Participants who have received ... radiotherapy treatment within the last 4 weeks prior to starting treatment and/or have not recovered from toxicities to less than grade 2 CTCAE
Cannot have received: investigational therapy
Participants receiving other investigational therapies
Lab requirements
Blood counts
Hemoglobin >= 9.0 gm/dL; ANC >= 1,500/mm^3; Platelets >= 75,000/mm^3
Kidney function
Creatinine within normal institutional limits or creatinine clearance >60 mL/min/1.73 m^2 for participants with creatinine levels above institutional normal calculated using eGFR
Liver function
AST and ALT <= 3 x ULN; Bilirubin <= 2 x ULN
Adequate organ function, including: Hemoglobin >= 9.0 gm/dL; ANC >= 1,500/mm^3; Platelets >= 75,000/mm^3; AST and ALT <= 3 x ULN; Bilirubin <= 2 x ULN; Creatinine within normal institutional limits or creatinine clearance >60 mL/min/1.73 m^2 for participants with creatinine levels above institutional normal calculated using eGFR.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- National Institutes of Health Clinical Center · Bethesda, Maryland
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify